Yesterday's extended and updated data of the MERECA study, provided by the company, gives us a somewhat more positive view of the trial results. In particular, we believe that the longer duration of response seen in the ilixadencel arm is very promising, and finds positive signs when it comes to survival (mOS still not reached) and CD8+ T cell infiltration.